Purpose: Rilpivirine, prescribed for the treatment of HIV infection, presents an important inter-individual pharmacokinetic variability. We aimed to determine population pharmacokinetic parameters of rilpivirine in adult HIV-infected patients and quantify their inter-individual variability.

Methods: We conducted a multicenter, retrospective, and observational study in patients treated with the once-daily rilpivirine/tenofovir disoproxil fumarate/emtricitabine regimen. As part of routine therapeutic drug monitoring, rilpivirine concentrations were measured by UPLC-MS/MS. Population pharmacokinetic analysis was performed using NONMEM software. Once the compartmental and random effects models were selected, covariates were tested to explain the inter-individual variability in pharmacokinetic parameters. The final model qualification was performed by both statistical and graphical methods.

Results: We included 379 patients, resulting in the analysis of 779 rilpivirine plasma concentrations. Of the observed trough individual plasma concentrations, 24.4% were below the 50 ng/ml minimal effective concentration. A one-compartment model with first-order absorption best described the data. The estimated fixed effect for plasma apparent clearance and distribution volume were 9 L/h and 321 L, respectively, resulting in a half-life of 25.2 h. The common inter-individual variability for both parameters was 34.1% at both the first and the second occasions. The inter-individual variability of clearance was 30.3%.

Conclusions: Our results showed a terminal half-life lower than reported and a high proportion of patients with suboptimal rilpivirine concentrations, which highlights the interest of using therapeutic drug monitoring in clinical practice. The population analysis performed with data from "real-life" conditions resulted in reliable post hoc estimates of pharmacokinetic parameters, suitable for individualization of dosing regimen.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-017-2405-1DOI Listing

Publication Analysis

Top Keywords

pharmacokinetic parameters
12
inter-individual variability
12
patients treated
8
population pharmacokinetic
8
therapeutic drug
8
drug monitoring
8
rilpivirine concentrations
8
analysis performed
8
plasma concentrations
8
rilpivirine
6

Similar Publications

Article Synopsis
  • CAB + RPV is the first long-acting HIV treatment regimen using thigh injections, showing promising results in maintaining viral suppression.
  • The study involved 118 participants and compared pharmacokinetic changes and tolerability between thigh and gluteal injections, finding no significant differences in effectiveness.
  • Results indicated that a majority of participants preferred thigh injections, with potential plans for more flexible dosing schedules to enhance treatment convenience.
View Article and Find Full Text PDF

A mutual prodrug of sertraline-methylpropyphenazone (SER-MP) was prepared and characterized using a spectral method. The yield of the prepared SER-MP was 90%, and its purity reached 98.8%.

View Article and Find Full Text PDF

Administration Studies in Equine Antidoping Research: Designing Scientific Investigations to Effectively Direct Medication Control in Racehorses.

Drug Test Anal

January 2025

KL Maddy Equine Analytical Chemistry Lab (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, California, USA.

Article Synopsis
  • Pharmacokinetics studies how drugs move through the body, focusing on absorption, distribution, metabolism, and excretion, while pharmacodynamics examines the drug's effects on the body.
  • The combination of pharmacokinetic and pharmacodynamic studies helps correlate drug concentrations with their therapeutic effects, providing valuable data for regulatory purposes and establishing administration guidelines.
  • Key considerations for pharmacokinetic studies include subject characteristics, dosages, sample types, collection times, and analytical methods to ensure accurate assessment of drug effects and concentrations.
View Article and Find Full Text PDF
Article Synopsis
  • The study compared the bioavailability of the anti-interleukin-5 antibody depemokimab when delivered using a safety syringe device (SSD) versus an autoinjector (AI) in healthy adults.
  • Both methods showed similar plasma concentration profiles and pharmacokinetic parameters, confirming that they are bioequivalent.
  • Adverse events were minor and comparable between the two delivery methods, with headaches being the most common side effect, indicating both devices are safe for administering depemokimab.
View Article and Find Full Text PDF

Background: The optimal pharmacokinetic and pharmacodynamic (PK/PD) parameters of vancomycin that can improve outcomes in enterococcal infections remain controversial. To clarify the therapeutic target for this antibiotic, this study aimed to determine vancomycin PK/PD parameters associated with efficacy in the early (during 72 h) or later (after 72 h) phase of treatment and nephrotoxicity in enterococcal bloodstream infection patients.

Methods: This multicenter retrospective study reviewed medical records of patients with enterococcal bloodstream infections treated with intravenous vancomycin infusion for at least 72 h between January 2016 and March 2024 at Phramongkutklao Hospital or Nopparatrajathanee Hospital in Bangkok, and Rachaburi Hospital in Rachaburi Province, Thailand.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!